Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 5, 2014, Pages 466-479

  Angelo, Maria Genalin ^a   David, Marie Pierre ^a   Zima, Julia ^a   Baril, Laurence ^a   Dubin, Gary ^b   Arellano, Felix ^a   Struyf, Frank ^a  

^a GSK   (Belgium)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Adverse drug reactions; AS04; Autoimmune disease; Human papillomavirus vaccine; Pharmacoepidemiology; Pregnancy; Safety

Indexed keywords

ADJUVANT; VACCINE; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT;

ADDISON DISEASE; ADOLESCENT; ADULT; ALOPECIA AREATA; ANAPHYLAXIS; APPENDICITIS; ARTICLE; AUTOIMMUNE THYROIDITIS; BRONCHITIS; CELIAC DISEASE; CHILD; CHLAMYDIASIS; CONGENITAL MALFORMATION; CONSTIPATION; CONTROLLED STUDY; CRANIAL NEUROPATHY; CROHN DISEASE; DEATH; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; FOLLOW UP; GONORRHEA; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE MEDIATED INJURY; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; LICHEN PLANUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NARCOLEPSY; NEURITIS; OTALGIA; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREMATURITY; PRIORITY JOURNAL; PROCTITIS; PSORIASIS; PSORIATIC ARTHRITIS; RAYNAUD PHENOMENON; REACTIVE ARTHRITIS; RESPIRATORY TRACT INFECTION; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHOOL CHILD; SKIN LUPUS ERYTHEMATOSUS; SPONTANEOUS ABORTION; STEVENS JOHNSON SYNDROME; STILLBIRTH; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ULCERATIVE COLITIS; VACCINATION; VASCULITIS; VITILIGO; AGED; META ANALYSIS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; RISK; TIME; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; RISK; TIME FACTORS; YOUNG ADULT;

EID: 84898023238     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3554     Document Type: Article

References (44)

1. De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056.
2. Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011; 29: 4453-4459.
3. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
4. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
5. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.
6. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-110.
7. Roteli-Martins C, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8. http://www.ncbi.nlm.nih.gov/pubmed/22327492 (accessed 20 Apr 2012).
8. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 2010; 20: 847-855.
9. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3years in young adult women. Vaccine 2010; 28: 6247-6255.
10. Angelo M, Zima J, Tavares F, Baril L, Arellano F. Post-licensure safety surveillance for AS04-adjuvanted Human Papillomavirus vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf submitted for publication.
11. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5: 332-340.
12. Tavares F, De Keyser F, Lambert P-H, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013; 31(14): 1870-1876. DOI: 10.1016/j.vaccine.2013.01.042.
13. Salemi S, D'Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol 2010; 29: 247-269.
14. Schattner A, Rager-Zisman B. Virus-induced autoimmunity. Rev Infect Dis 1990; 12: 204-222.
15. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005; 38: 235-245.
16. Verstraeten T, Descamps D, David M-P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26: 6630-6638.
17. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2011. doi: 10.1111/j.1365-2796.2011.02467.x.
18. Saraiya M, Berg CJ, Shulman H, Green CA, Atrash HK. Estimates of the annual number of clinically recognized pregnancies in the United States, 1981-1991. Am J Epidemiol 1999; 149: 1025-1029.
19. Seamark C. Design or accident? The natural history of teenage pregnancy. J R Soc Med 2001; 94: 282-285.
20. Ventura SJ, Abma JC, Mosher WD, Henshaw SK. Estimated pregnancy rates by outcome for the United States, 1990-2004. Natl Vital Stat Rep 2008; 56: 1-25, 28.
21. Devine S, West S, Andrews E, et al. The identification of pregnancies within the general practice research database. Pharmacoepidemiol Drug Saf 2010; 19: 45-50.
22. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010; 340: c712.
23. Szarewski A, Poppe WAJ, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2011. doi: 10.1002/ijc.26362.
24. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40: 564-571.
25. Petäjä T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011; 129: 2147-2157.
26. Medina DMR, Valencia A, De Velasquez A, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 2010; 46: 414-421.
27. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55years. Vaccine 2009; 27: 581-587.
28. Schwarz TF, Huang L-M, Medina DMR, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14years. J Adolesc Health 2012; 50: 187-194.
29. Schwarz TF, Spaczynski M, Schneider A, et al. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55years. Hum Vaccin 2011; 7: 958-965.
30. Herrero R, Wacholder S, Rodríguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1: 408-419.
31. Kreimer AR, González P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011; 12: 862-870.
32. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103: 1444-1451.
33. Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 2010; 36: 123-132.
34. Kim Y-J, Kim K-T, Kim J-H, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14years. J Korean Med Sci 2010; 25: 1197-1204.
35. Ngan HYS, Cheung ANY, Tam KF, et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J 2010; 16: 171-179.
36. Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18years of age: results from a randomized open trial. Pediatr Infect Dis J 2011; 30: e225-e234.
37. Leroux-Roels G, Haelterman E, Maes C, et al. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. Clin Vaccine Immunol 2011; 18: 1510-1518.
38. Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health 2012; 50: 38-46.
39. Schmeink CE, Bekkers RLM, Josefsson A, et al. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine 2011; 29: 9276-9283.
40. Garcia-Sicilia J, Schwarz TF, Carmona A, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010; 46: 142-151.
41. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45years. Hum Vaccin 2009; 5: 705-719.
42. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45years. Hum Vaccin 2011; 7: 1343-1358.
43. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45years. Hum Vaccin 2011; 7: 1359-1373.
44. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7: 1374-1386.